Melanoma driver mutations and immune therapy

Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations' impact on immunotherapy outcomes is unclear. We assessed 229 patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncoimmunology
Main Authors: Johnson, Douglas B., Lovly, Christine M., Sullivan, Ryan J., Carvajal, Richard D., Sosman, Jeffrey A.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2016
Teme:
Author's View
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910708/
https://ncbi.nlm.nih.gov/pubmed/27467925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1051299
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki